Rajiv Anand, Founder and CEO, Quartic.ai

Global Business Reports — September 12, 2020

Bright Path Labs has a technology that brings speed to the commercialization of API production. Continuous manufacturing is a big need in the pharmaceutical sector and Bright Path labs technology accelerates that process. In order to enable and commercialize the technology they needed modern automation. It became a natural fit for us to work together, as their method of manufacturing can be accelerated with use of machine learning and AI. In moving from one molecule to the other molecule in the same reactor it is a challenge to get to quality production quickly. They are using inline monitoring (ILM), which are analytic measurements, generally done offline. That is typical for a batch process. However, if you have a continuous process you need to do those measurements online. Quartic is able to use online measurements to create closed loop control. This creates a semi autonomous control system. It has basic automation that is going to control the equipment but the basic automation is being guided by AI models, which will be trained for particular molecules. For each molecule, we know what the perfect set points will be to achieve a quality target quickly.

About Bright Path Laboratories, Inc.

Bright Path Laboratories, Inc. is a commercial stage bio-pharmaceutical manufacturing company, dedicated to developing best-in-class continuous-flow manufacturing for the pharmaceutical sector.  For more information, please visit www.brightpathlabs.com.

Safe Harbor

To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Bright Path Pharmaceuticals’ plans, objectives, expectations and intentions with respect to cash flow requirements, future operations and products, and development activities, and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Bright Path Pharmaceuticals’ actual results to be materially different than those expressed in or implied by Bright Path Pharmaceuticals’ forward-looking statements. For Bright Path Pharmaceuticals, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the success and design of manufacturing facilities; and Bright Path Pharmaceuticals’ need for and ability to obtain additional financing. Bright Path Pharmaceuticals undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.